Please assess the completion status of the following clinical trial:

Trial Title: Personalized Variable Versus Fixed Dose Glucocorticoid Therapy in AECOPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Exacerbation of COPD as defined by the presence of at least 2 of the following: change in baseline dyspnea, cough, or sputum quantity or purulence.~Exclusion Criteria:~* Signs of severe exacerbation (arterial pH \< 7.26 or PaCO2 \> 9.3 kPa)~* History of asthma~* Significant or unstable co-morbidity~* Participated in another study 4 weeks before admission~* Previously randomized to this study~* Known hypersensitivity to prednisolone~* Inability to give written informed consent~* Radiological diagnosis of pneumonia~* Estimated survival of less than 6 months due to severe comorbidity~* Use of glucocorticoid within 1 month before admission

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Personalized variable dose of glucocorticoids arm (Type: EXPERIMENTAL): Use of personalized variable dose of glucocorticoids according to a rating scale starting from the first day of hospitalization for 5 days, together with other necessary treatments, including antibiotics, Inhaled corticosteroid (ICS), long-acting beta2-agonist (LABA), Long-Acting Muscarinic Antagonists(LAMA), short-acting beta2-agonist (SABA), and other physical treatments.
- Fixed dose of glucocorticoids arm (Type: OTHER): Use of fixed term of glucocorticoids (40mg) starting from the first day of hospitalization for 5 days, together with other necessary treatments, including antibiotics, ICS, LABA, LAMA, SABA, and other physical treatments.

Based on this trial design, predict the completion outcome and termination type (if applicable).